COVID-19 drug trial pulled before it even started
NCT ID NCT04356677
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study planned to test an inhaled medicine called Virazole (ribavirin) in adults hospitalized with COVID-19 who had serious breathing trouble. The goal was to see if the drug was safe and could improve oxygen levels. However, the trial was withdrawn before enrolling any volunteers, so no results were obtained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Virazole (ribavirin) given as an inhaled mist
- What this could lead to
- If it worked, this could point toward a treatment for severe COVID-19 breathing distress.
- What could go wrong
- The study was withdrawn before any participants were enrolled, so no results are available. Ribavirin has known side effects and may not be effective against COVID-19.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a different way of pedaling rebuild muscles after severe COVID-19?
- Ancient herbs take on long COVID: a trial tests whether chinese medicine can soothe persistent fatigue
- Can a 15-Minute chat at a testing site boost COVID-19 vaccination?
- E-Ink screens in ERs could boost patient satisfaction
- Massive study tracks how lockdowns shaped mental health across america
- Hidden danger: study probes blood clot risk in cancer patients with COVID-19